Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Osinkohistoria IMAB
Osinkoanalytiikka IMAB
Max Ratio
–Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–I-Mab
IMABI-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. Address: 2440 Research Boulevard, Rockville, MD, United States, 20850
Analytics
WallStreetin tavoitehinta
5.60 USDP/E-suhde
–Osinkotuotto
–Talousasiat IMAB
Tuloksia | 2019 | Dynamiikka |